Charite - Campus Benjamin Franklin, Department of Rheumatology , Hindenburgdamm 30, 12203 Berlin , Germany.
Expert Opin Drug Saf. 2011 Jul;10(4):655-73. doi: 10.1517/14740338.2011.581661. Epub 2011 May 10.
In the last couple of years, the number of patients with chronic inflammatory rheumatic diseases being treated with TNF α antagonist has increased dramatically. Adalimumab, a fully human monoclonal antibody against TNF α, is one of the most frequently administered TNF α antagonists. Yet, unresolved issues are the long-term safety of TNF α antagonists and high treatment costs.
The authors summarize the available data on short- and long-term efficacy and safety of adalimumab in the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. The reader will find a comprehensive overview on the safety and efficacy of adalimumab for these conditions. Clinically relevant questions of adalimumab therapy are discussed. A special focus of this review is on the safety of adalimumab therapy.
Adalimumab is effective and reasonably safe in the short- and long-term treatment of patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis who do not respond to the standard therapy. It inhibits radiographic progression in rheumatoid and psoriatic arthritis. Treatment with a TNF α inhibitor such as adalimumab is associated with high treatment costs.
在过去的几年中，接受 TNFα 拮抗剂治疗的慢性炎症性风湿性疾病患者数量急剧增加。阿达木单抗是一种针对 TNFα 的全人源单克隆抗体，是最常使用的 TNFα 拮抗剂之一。然而，尚未解决的问题是 TNFα 拮抗剂的长期安全性和高昂的治疗费用。
作者总结了阿达木单抗治疗类风湿关节炎、强直性脊柱炎和银屑病关节炎的短期和长期疗效和安全性的现有数据。读者将全面了解阿达木单抗治疗这些疾病的安全性和疗效。讨论了阿达木单抗治疗的临床相关问题。本综述的一个特别重点是阿达木单抗治疗的安全性。
阿达木单抗在治疗对标准治疗无反应的类风湿关节炎、强直性脊柱炎和银屑病关节炎患者的短期和长期治疗中是有效且相对安全的。它可抑制类风湿关节炎和银屑病关节炎的放射学进展。使用 TNFα 抑制剂（如阿达木单抗）治疗与高昂的治疗费用相关。
